Evolution of resistance to thyroid cancer therapy

Carmelo Nucera

doi:10.18632/aging.101030

Evolution of resistance to thyroid cancer therapy

Aging (Albany NY). 2016 Aug;8(8):1576-7. doi: 10.18632/aging.101030.

Author

Carmelo Nucera¹

Affiliation

¹ Laboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

No abstract available

Keywords: BRAFV600E inhibitors; BRAFV600E papillary thyroid cancer pre-clinical model; MCL1 somatic copy number; clonal evolution; microenvironment; resistance.

Publication types

Editorial
Comment

MeSH terms

Humans
Mutation*
Thyroid Neoplasms*

Grants and funding

R01 CA181183/CA/NCI NIH HHS/United States